Feedback (FDBK) Share Price, News & Analysis

Company Overview

Feedback plc, a medical imaging technology company, engages in the provision of software and systems to those working in the field of medical imaging. Its products include Bleepa, a secure clinical communications and data viewing platform that facilitates the sharing of clinical-grade medical images; CareLocker, a patient centric cloud architecture that provides secure data portability; and Bleepa Box, a technology for sharing DICOM images and other clinical data over mobile networks with the company's dedicated cloud environment, CareLocker, for subsequent display and review within Bleepa. The company also offers Cadran, a picture archiving storage, management, and display system for medical images; TexRAD, a patent-protected algorithm that extracts and quantifies texture features in pre-existing medical images; and TexRAD Lung, a software tool for the analysis of lung cancer for clinical use. Feedback plc was incorporated in 1958 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: 20 to 20.90
• 50-Day Range: 19.93 to 64.46
• 52-Week Range: 19 to 152.92
• Volume: 4,973 shs
• Average Volume: 39,340 shs
• Market Capitalization: £2.73 million
• P/E Ratio: N/A
• Dividend Yield: 4.56%
• Price Target: N/A
• Consensus Rating: N/A

FDBK Stock Analysis - Frequently Asked Questions

How have FDBK shares performed this year?

Feedback's stock was trading at GBX 67.50 at the start of the year. Since then, FDBK stock has decreased by 69.6% and is now trading at GBX 20.50.
View the best growth stocks for 2024 here.

How were Feedback's earnings last quarter?

Feedback plc (LON:FDBK) issued its quarterly earnings results on Tuesday, February, 18th. The company reported ($26.00) earnings per share (EPS) for the quarter. Feedback had a negative net margin of 279.16% and a negative trailing twelve-month return on equity of 35.63%.

When did Feedback's stock split?

Shares of Feedback reverse split before market open on Friday, October 14th 2022. The 1-200 reverse split was announced on Friday, October 14th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Feedback?

Shares of FDBK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Feedback own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Feedback investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), Quadrise Fuels International (QFI), Advanced Oncotherapy (AVO), B&M European Value Retail (BME), Coats Group (COA) and genedrive (GDR).

Company Calendar

• Last Earnings: 2/18/2020
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:FDBK
• CUSIP: N/A
• CIK: N/A
• Web: www.fbk.com
• Phone: +44-1954-718072
• Fax: N/A
• Employees: 24
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-3,300,000.00
• Net Margins: -279.16%
• Pretax Margin: N/A
• Return on Equity: -35.63%
• Return on Assets: -22.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.13
• Quick Ratio: 18.41

Sales & Book Value

• Annual Sales: £1.18 million
• Price / Sales: 2.26
• Cash Flow: GBX 17.87 per share
• Price / Cash Flow: 1.12
• Book Value: GBX 57 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 13,330,000
• Free Float: N/A
• Market Cap: £2.67 million
• Optionable: Not Optionable
• Beta: 0.77